専門分野

医療技術評価、費用効果分析、アウトカム研究、生物統計学、医療経済学

人材育成

短期研修
1 保健医療事業の経済的評価に関する研修　　主任

研究実績

原著論文

1 Kawahara T, Taira N, Shiroiwa T, Hagiwara Y, Fukuda T, Uemura Y, Mukai H. Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial. Qual Life Res 2022;31(6):1829-1836.

2 Shiroiwa T, Nakamura-Thomas H, Yamaguchi M, Morikawa M, Moriyama Y, Fukuda T, Allan S, Malley J. Japanese preference weights of the Adult Social Care Outcomes Toolkit for Carers (ASCOT-Carer). Qual Life Res. 2022;31(7):2143-2151.

3 Shibahara H, Shiroiwa T, Ishiguro M, Nakamura M, Hasegawa J, Yamaguchi S, Masuda Y, Sakamoto J, Tomita N, Fukuda T. Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study. Eur J Health Econ. 2022;23(7):1159-1171.

4 Hagiwara Y, Shiroiwa T. Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches. Med Decis Making. 2022;42(5):672-683.

5 Akiyama N, Uozumi R, Akiyama T, Koeda K, Shiroiwa T, Ogasawara K. Choking injuries: Associated factors and error-producing conditions among acute hospital patients in Japan. PLoS One. 2022;17(4):e0267430

6 Takumoto Y, Shiroiwa T, Shimozuma K, Iwata H, Takahashi M, Baba S, Kobayashi K, Hagiwara Y, Kawahara T, Uemura Y, Mukai H, Taira N, Sawaki M. Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial. Clin Drug Investig. 2022;42(3):253-262.

7 Akiyama N, Kajiwara S, Shiroiwa T, Akiyama T, Morikawa M. Reported Incidents Involving Non-medical Care Workers and Nursery Teachers in Hospitals in Japan: An Analysis of the Japan Council for Quality Health Care Nationwide Database. Cureus. 2022;14(2):e22589.

8 Hagiwara Y, Shiroiwa T, Taira N, Kawahara T, Konomura K, Noto S, Fukuda T, Shimozuma K. Gradient Boosted Tree Approaches for Mapping European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Onto 5-Level Version of EQ-5D Index for Patients With Cancer. Value Health. 2022 Sep 9;S1098-3015(22)02140-4. doi: 10.1016/j.jval.2022.07.020.

9 Shiroiwa T, Murata T, Ahn J, Li X, Nakamura R, Teerawattananon Y, Kun Z, Shafie AA, Valverde H, Lam H, Ng K, Nadjib M, Pwu RF, Nugraha RR, Chen YC, Fukuda T. Developing a New Region-Specific Preference-Based Measure in East and Southeast Asia. Value Health Reg Issues. 2022;32:62-69.